FEATURE
TABLE 2 VACCINE EFFICACY OF RZV AGAINST HERPES ZOSTER INFECTION (7)
# # confirmed
cases Follow up
Person
yrs. Rate HZ Per
1000 Person
yrs. Vaccine
efficacy
VE% (95%
Cl)
0.3 7415 210 23170.5 9.1 97.2
(93.7- 99.0)
11,161.3 0.3 3525 87 11,134.7 7.8 96.9
(89.6-99.3)
2 7007.9 0.3 2166 75 6952.7 10.8 97.4
(90.1-99.7)
1 5129.7 0.2 1724 48 5083.0 9.4 91.3
(86.8-94.5)
# # confirmed
cases Follow up
Persons
yrs. Rate of HZ Per
1000 Person yrs.
All persons 7344 6 23,297.0 50-59 3492 3 60-69 2141 70 1711 Age Group
Two doses
VE = Vaccine Efficacy, P = < 0.001 for all comparisons
Herpes Zoster
• About 90% of HZ episodes associated with pain
• Treatment: antivirals reduce duration of rash and pain 1
PHN
• Pain at least 90 days following resolution of rash
2
• Treatment: minimal or no efficacy. Side effects, especially in elderly
Cohen et al, NEJM 2013, 2. Johnson et al, NEJM 2014
“My PHN is worse than my cancer and chemotherapy ... [it] has
made me depressed and suicidal in the past”
APRIL 2018
15